4:17 PM ET
10-Q
Financial Results
Oncolytics Biotech Q3 2026 Results: Net Loss of $9.71M, Loss Narrows
Oncolytics Biotech Inc. reported a net loss of $28.4 million for the nine months ended September 30, 2026, compared to $19.9 million in the prior year period, driven by increased R&D and G&A expenses. The company's cash position decreased to $2.4 million, leading management to issue a going concern warning as existing resources are insufficient to fund operations for the next twelve months.
- Key figure
- Net loss $9.71M